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Low dose chloroquine decreases insulin
resistance in human metabolic syndrome
but does not reduce carotid intima‑media
thickness
Janet B. McGill1*† , Mariko Johnson1†, Stacy Hurst1, William T. Cade2, Kevin E. Yarasheski1, Richard E. Ostlund1,
Kenneth B. Schechtman3, Babak Razani4, Michael B. Kastan5, Donald A. McClain6, Lisa de las Fuentes4,
Victor G. Davila‑Roman4, Daniel S. Ory4, Samuel A. Wickline4 and Clay F. Semenkovich1,7*

Abstract
Background: Metabolic syndrome, an obesity-related condition associated with insulin resistance and low-grade
inflammation, leads to diabetes, cardiovascular diseases, cancer, osteoarthritis, and other disorders. Optimal therapy
is unknown. The antimalarial drug chloroquine activates the kinase ataxia telangiectasia mutated (ATM), improves
metabolic syndrome and reduces atherosclerosis in mice. To translate this observation to humans, we conducted two
clinical trials of chloroquine in people with the metabolic syndrome.
Methods: Eligibility included adults with at least 3 criteria of metabolic syndrome but who did not have diabetes.
Subjects were studied in the setting of a single academic health center. The specific hypothesis: chloroquine improves
insulin sensitivity and decreases atherosclerosis. In Trial 1, the intervention was chloroquine dose escalations in 3-week
intervals followed by hyperinsulinemic euglycemic clamps. Trial 2 was a parallel design randomized clinical trial, and
the intervention was chloroquine, 80 mg/day, or placebo for 1 year. The primary outcomes were clamp determinedinsulin sensitivity for Trial 1, and carotid intima-media thickness (CIMT) for Trial 2. For Trial 2, subjects were allocated
based on a randomization sequence using a protocol in blocks of 8. Participants, care givers, and those assessing
outcomes were blinded to group assignment.
Results: For Trial 1, 25 patients were studied. Chloroquine increased hepatic insulin sensitivity without affecting
glucose disposal, and improved serum lipids. For Trial 2, 116 patients were randomized, 59 to chloroquine (56 ana‑
lyzed) and 57 to placebo (51 analyzed). Chloroquine had no effect on CIMT or carotid contrast enhancement by MRI,
a pre-specified secondary outcome. The pre-specified secondary outcomes of blood pressure, lipids, and activation of
JNK (a stress kinase implicated in diabetes and atherosclerosis) were decreased by chloroquine. Adverse events were
similar between groups.
Conclusions: These findings suggest that low dose chloroquine, which improves the metabolic syndrome through
ATM-dependent mechanisms in mice, modestly improves components of the metabolic syndrome in humans but is
unlikely to be clinically useful in this setting.
Trial registration ClinicalTrials.gov (NCT00455325, NCT00455403), both posted 03 April 2007
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Introduction
A combination of increased triglycerides, low HDL cholesterol, hypertension, above normal fasting glucose, and
increased waist circumference constitutes the metabolic
syndrome [1], which predisposes to diabetes, cardiovascular disease, and all-cause mortality [2]. Current therapy
is directed at individual components of the syndrome,
which are related to insulin resistance. Obesity-related
insulin resistance is associated with low-grade systemic
inflammation characterized by increased activation of a
stress kinase known to induce insulin resistance, c-Jun
N-terminal kinase (JNK) [3]. Pronounced weight loss is
associated with decreased cardiovascular events [4], but
there are other causes of insulin resistance besides obesity that could provide insight into relationships between
insulin resistance and cardiovascular disease. DNA damage disorders including Hutchinson–Gilford progeria,
Werner syndrome, Cockayne syndrome, and ataxia telangiectasia are associated with insulin resistance and vascular disease [5]. Mice deficient in ataxia telangiectasia
mutated (ATM), the kinase mutated in ataxia telangiectasia, have increased activation of JNK in macrophages,
insulin resistance, hypertension, and increased atherosclerosis [6–8]. ATM activation by the anti-malarial drug
chloroquine decreases macrophage JNK activation, blood
pressure, insulin resistance, and atherosclerosis in mice
[6, 9].
Since the ATM axis is associated with altered hepatic
insulin sensitivity and atherosclerosis in mice, we translated these rodent data to humans with metabolic syndrome in two exploratory clinical trials: (1) A dose
escalation study with a primary endpoint of insulin sensitivity and pre-specified secondary endpoints including
serum lipids and blood pressure; and (2) Placebo or chloroquine treatment for 1 year with a primary endpoint of
carotid intima-media thickness, a noninvasive predictor
of cardiovascular events [10]. The 1 year study utilized
the lowest dose associated with improved insulin sensitivity in the dose escalation study and included pre-specified secondary endpoints such as carotid MRI, activation
of JNK in isolated monocytes, serum lipids, and blood
pressure.
Subjects and methods
Subjects and trial design

These single center studies were approved by the Washington University Human Research Protection Office. All
subjects gave informed consent and were compensated

for their participation. A data safety and monitoring
board convened by the National Heart, Lung and Blood
Institute (NHLBI) supervised the trials.
For both the dose escalation and double blind trials, inclusion criteria included men and women of any
ethnic group between the ages of 18–60 (Trial 1), and
18–70 (Trial 2) (the difference in age between protocols
was intended to make the randomized trial more pertinent to a broader age group) who had at least 3 of the
components of the metabolic syndrome: elevated fasting triglycerides (≥ 1.69 mmol/L); low HDL cholesterol
(< 1.29 mmol/L in women, < 1.03 mmol/L in men); hypertension (≥ 130/85 mm Hg ≤ 160/100 mmHg) untreated,
or hypertension controlled (≤ 150/90 mm Hg) on a stable medication regimen; increased waist circumference
(> 89 cm in women, > 102 cm in men); elevated fasting
glucose (≥ 5.6 mmol/L and < 7.0 mmol/L). For a diagnosis of hypertension, measurements were repeated on two
separate days. Fasting glucose was also repeated on two
separate days. Fasting lipids were performed once before
enrollment but repeated throughout the interventions.
Exclusion criteria were extensive and included: known
prior treatment with chloroquine or hydroxychloroquine, BMI > 45 kg/m2, coronary artery disease or other
vascular disease, history of stroke, eGFR (estimated glomerular filtration rate) < 60 ml/min/1.73 m2, diabetes,
seizure disorder, history of psoriasis, hematological disorders (including anemia), current malignancy, asthma
or COPD (chronic obstructive pulmonary disease), liver
disease (including transaminases > 2× upper limit of
normal), active infection (including HIV-human immunodeficiency virus), any serious illness requiring ongoing medical care, major psychiatric illness, lipid lowering
medications (other than statins and < 1 g daily fish oils),
severe hypertension at baseline or taking more than
three antihypertensives, use of cimetidine or vitamin E,
pregnancy or lactation or intention to become pregnant,
inadequate use of contraception, glucose-6-phosphate
dehydrogenase deficiency, auditory disease or hearing
loss, retinal disease (especially presence of drusen or pigmentary changes at the macula), and any ocular disease
interfering with the ability to rigorously assess the retina.
A CONSORT statement flow diagram for the first trial
is shown in Fig. 1. The study design for the first trial is
shown in Fig. 2a. One hundred forty-four subjects were
screened for participation in Trial 1 and 35 individuals
with the metabolic syndrome qualified. Twenty-five subjects completed the protocol. Ten discontinued the study
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Fig. 1 CONSORT statement flow diagram for subjects in dose escalation study

Page 3 of 16

McGill et al. Diabetol Metab Syndr

(2019) 11:61

Page 4 of 16

(See figure on next page.)
Fig. 2 Chloroquine dose escalation trial design and results for hyperinsulinemic-euglycemic clamping and lipids. a Diagram of the dose escalation
protocol. A 5–7 week washout period was required between limbs to allow for hematologic recovery following the blood drawing associated with
clamps. b Glucose disposal rates expressed as μmol glucose/kg body weight/min. Insulin infusion rates were 0, 56, 181, or 486 pmol/m2/min. c
Hepatic glucose production expressed as (μmol glucose/kg body weight/min) per pmol/L insulin. d Hepatic insulin sensitivity expressed as percent
suppression of glucose production at 56 pmol/m2/min. e Total, non-HDL, and LDL cholesterol at the end of each limb. f Triglycerides and HDL
cholesterol at the end of each limb. Data represent mean ± SE. *P < 0.05 by Tukey’s test for multiple comparisons after repeated measures ANOVA

for reasons that included: starting a new medication during the protocol [3], new diagnosis of diabetes during
the protocol [1], difficult IV access [1], worsening joint
symptoms [1], and miscellaneous issues unrelated to
the protocol (such as relocation, 4). For this single blind,
placebo-controlled study, each subject took a capsule that
was identical in appearance for 21 days. For the first limb,
capsule contents were inert. For the second limb, three
of the 21 capsules (administered at weekly intervals) contained 80 mg of chloroquine and the remaining capsules
were inert. For the third and fourth limbs, capsules contained 80 or 250 mg of chloroquine, respectively. Each
limb was separated by a washout period to allow recovery from the blood drawing of the clamp procedure.
It was not possible to randomize limb order due to the
extremely long half-life of chloroquine; ingestion during
an early limb would be associated with tissue levels of the
drug and its metabolites during a later placebo limb.
A CONSORT statement flow diagram for the second
trial is shown in Fig. 3. The study design for the second
trial is shown in Fig. 4a. The blind was held by a research
pharmacist, who provided the randomization sequence
to the blinded research nurses or physicians who enrolled
participants and assigned interventions that included
study medications that were identical in appearance.
Three hundred fifty-seven subjects were screened for
participation in Trial 2 and 155 non-diabetic individuals
with metabolic syndrome qualified at the initial screening visit. Of these, 21 withdrew consent before the second screening visit, 4 withdrew consent after the second
screening visit and 14 did not qualify for randomization
due to abnormal eye exams [4], abnormal carotid imaging [2], anemia [3], G6PD deficiency [2], abnormal liver
function tests [2], and psoriasis [1]. The remaining 116
subjects were randomized to placebo or chloroquine.
Of those randomized, 19 assigned to placebo and 20
assigned to chloroquine were being treated for hypertension, and were taking 1.3 ± 1.1 and 1.1 ± 1.0 antihypertensive medications respectively. 15 subjects in each
group were taking a statin.
Hyperinsulinemic–euglycemic clamp procedure

At the end of each limb depicted in Fig. 2a, subjects presented after an overnight fast. The antecubital vein was
catheterized for infusion of insulin, glucose and tracer

solutions, a hand vein was catheterized for blood sampling, and the hand was maintained in a hotbox at ~ 55 °C
to arterialize venous sampling. Baseline samples were
obtained prior to initiating infusions.
Insulin sensitivity was assayed using a two-step euglycemic clamp technique as described previously [11]. The
stable isotope [6,6-2H2] glucose (22 μmol/kg prime and
0.25 μmol/kg/min constant infusion) was infused during
a 90 min basal period (to allow isotope equilibration) and
then continued throughout each study. Plasma glucose
was measured at 5–10 min intervals following the basal
period. Insulin was initially infused in two stages consisting of rates of 181 and 486 pmol/m2/min, but after analyzing results from the first 7 patients, the protocol was
modified to include two stages consisting of insulin infusion rates of 56 and 181 pmol/m2/min in order to avoid
nearly complete suppression of hepatic glucose production at higher insulin infusion rates. Twenty % dextrose
(containing 1.5% [6,6-2H2] glucose) was infused to maintain blood glucose at 5.00 mmol/L for ~ 2 h at each stage.
Plasma was assayed for 6,6-2H2-glucose enrichment by
mass spectrometry. Glucose kinetics were determined
using samples obtained at 10 min intervals during the last
30 min of the basal period and during each stage of the
clamp.
Glucose tolerance testing and assays of serum or plasma

Oral glucose tolerance testing was performed by administering 75 g of glucose followed by sampling at 0, 30,
60, 90 and 120 min. Samples were assayed for glucose,
insulin, C peptide, and glucagon. AUC calculations were
performed using the trapezoid rule for approximating
integrals. Lipids, lipoproteins, serum chemistries, and
blood counts were assayed by the Washington University
Core Laboratory for Clinical Studies, which is CLIA-certified. Since this project addressed the effects of chloroquine on insulin resistance, the cause of which remains
obscure, the laboratory also performed exploratory
measurements of putative metabolic mediators that have
been implicated in insulin resistance and/or its vascular
complications [12–16]. These included adiponectin, leptin, iron, VEGF (vascular endothelial growth factor), and
IL-17A. Samples for adiponectin and iron studies were
assayed at the University of Utah [17].
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Fig. 3 CONSORT statement flow diagram for subjects in the yearlong randomized clinical trial

Blood pressure determinations

Two techniques were employed: auscultation of seated
subjects at rest was performed by a trained observer
who recorded the first and fifth phases of the Korotkoff
sounds; and, a portable oscillometric device (SpaceLabs
Medical) recorded results every 20 min during the day
and every h during the night then data were analyzed as
mean values over 24 h, between 0800 and 2200 (daytime),
and between 2200 and 0800 (nighttime).
CIMT assessments

Carotid artery intima-media thickness (CIMT) was
measured from B-mode images by a single sonographer using standard approaches [18, 19]. The average of
3 measurements of the posterior wall of each common
carotid ~ 1 cm proximal to the carotid bulb was determined; plaques (wall thickening > 50% of the surrounding
wall) were excluded. To establish reproducibility, 10% of

the images were randomly selected and re-measured in
a blinded fashion by two independent observers. Intraobserver and inter-observer correlation coefficients were
0.900 and 0.992.
MRI assessments

A contouring tool on the Philips ViewForum workstation was used to outline the inner and outer common carotid artery wall regions (right and left) in the
first frame immediately below the bifurcation in the
T2-weighted image, then areas and diameters of the
vessel wall and lumen were calculated. The maximum
thickness of the common carotid in the same frame was
measured with the line tool. Similar measurements were
made for the internal carotid artery in a slice just beyond
the bifurcation. For common carotid artery wall contrast enhancement, which represents gadolinium leakage
and late hyper enhancement, pre- and post-injection T1
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weighted images were compared by dividing the artery
into quadrants. The slice nearest the bifurcation manifesting the greatest signal in terms of numbers of quadrants enhanced was chosen by visual comparison with
the same pre-injection slice. If the pre-injection signal
in the carotid wall appeared bright in any quadrant due
to signal spatial heterogeneity, and with reference to the
other arterial wall segments in adjacent or contralateral
arteries, then the post- injection signal was deemed nonenhancing. Concurrence of two readers was achieved in
blinded interpretations.
Monocyte protein preparation, JNK assays, and oxysterol
determinations

Human monocytes were isolated using a negative selection technique employing a RosetteSep Human Monocyte Enrichment Cocktail (StemCell Technologies
#15028), exactly as described by the manufacturer. Cells
were lysed using a buffer containing 1% Tween 20 and
0.2% NP40 with protease and phosphatase inhibitors, and
lysates were aliquoted and stored at − 80 °C.
Total and phospho (Thr183/Tyr185) JNK were assayed
using chemiluminescent sandwich ELISA kits (Cell Signaling Technologies #7869S and #7849S). Extracts from
subjects before and 1 year following treatment were
analyzed in the same assay by an observer masked to
randomization status. Signals detected from 1 μg lysate
protein (assayed with BCA reagents from Pierce) were
determined using a Synergy 4 plate reader and the ratio
of phospho-JNK to total JNK was calculated. For assays
of cholestane-3β,5α,6β-triol, plasma samples stored at
− 80 °C were thawed and combined with BHT (50 μg/
mL). Oxysterols were purified, derivatized, then quantified by GC–MS (m/z 456) in assays performed within
the linear response range of appropriate standard curves
[20].
Statistical analyses

Results are expressed as mean ± SD except in Fig. 2
where results are presented as mean ± SE to simplify
data presentation. Statistical analyses were performed
using GraphPad Prism software. For the dose escalation
study, most data were analyzed using repeated measures ANOVA with post hoc testing using Tukey’s multiple comparison test for inter-group differences. For the
yearlong treatment study, most data were analyzed using
a mixed model approach for repeated measures to allow
for dealing with missing values. P values for mixed model
analyses represent an assessment of whether the dependent variable was affected by the randomization group
(placebo vs. chloroquine) vs. time interaction. Some
analyses in both trials involving only two groups were
performed using a two-tailed Student’s t test. Spearman
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correlation coefficients were calculated for the relationships between baseline CIMT in the 116 randomized
subjects and variables associated with atherosclerosis.
Two-tailed paired t tests were used to analyze the baseline vs. 12-month results for MRI imaging and JNK activation. Binary baseline characteristics and adverse events
were analyzed using contingency tables and Chi Square
Test or Fisher’s Exact Test.

Results
Metabolic effects of increasing doses of chloroquine

Characteristics for those completing the dose escalation
study are shown in Table 1. The primary endpoint of the
first trial was clamp-determined insulin sensitivity. Twostage hyperinsulinemic euglycemic clamps were initially
performed using insulin at 181 and 486 pmol/m2/min.
However, data analysis after the first seven patients demonstrated complete suppression of glucose production at
the higher dose and nearly complete suppression at the
lower dose, decreasing the ability to detect differences in
endogenous glucose production in this group of patients
with metabolic syndrome but not diabetes. Subsequent
two-stage clamps were performed using insulin infusions
at 56 and 181 pmol/m2/min. The results from these first
seven patients are included in Fig. 2b, c; the 486 pmol/
m2/min condition represents data points from these first
patients for each limb while the 181 pmol/m2/min condition includes data points from these patients in addition to those from those undergoing clamps at 56 and
181 pmol/m2/min. There were no differences in glucose

Table 1 Baseline characteristics of subjects in the dose
escalation study
Variable

Results

Number

25

Gender (F/M)

18/7

Race
Black

2

Non-hispanic white

23

Weight (kg)
BMI (kg/m2)
Waist circumference (cm)
Fasting glucose (mmol/L)
Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)
Total cholesterol (mmol/L)
Non-HDL cholesterol (mmol/L)
LDL cholesterol (mmol/L)
Triglycerides (mmol/L)
HDL cholesterol (mmol/L)
Data represent mean ± SD

101 ± 17

35.0 ± 4.4
109 ± 13

5.27 ± 0.61
135 ± 16
80 ± 10

5.25 ± 0.67
4.11 ± 0.62
3.23 ± 0.57
1.85 ± 0.61
1.19 ± 0.26
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disposal rates between any of the chloroquine doses as
shown in Fig. 2b.
There was a dose-dependent effect of chloroquine
on hepatic glucose production (clamp-determined rate
of appearance) with significant suppression at doses of
80 mg/day and 250 mg/day as determined by repeated
measures ANOVA (Fig. 2c). Figure 2d shows that chloroquine increased hepatic insulin sensitivity based on data
from the 56 pmol/m2/min stage.
There was also an apparent dose-dependent effect of
chloroquine on fasting levels of total cholesterol, nonHDL cholesterol, and LDL cholesterol with a significant
decrease at 250/day as determined by repeated measures
ANOVA (Fig. 2e). Serum triglycerides and HDL cholesterol were unchanged (Fig. 2f ).
Chloroquine in this dose escalation study had no
effect on blood pressure determined using an ambulatory monitor as shown in Table 2. SBP, DBP, MAP, and
magnitude of BP decrease overnight (“dipping” status)

were unaffected in all limbs. Consistent with an effect
of chloroquine on hepatic insulin sensitivity, fasting glucose at the time of the clamp was significantly
decreased (Table 2). Consistent with the lack an effect
of chloroquine on glucose disposal, OGTT AUC results
were unaffected in all limbs (Table 2). There was also no
effect on body weight, glucagon, leptin, NEFA, C-peptide or insulin (Table 2).
There was a trend toward lower levels of TNFα
(Table 2), but other inflammatory markers including CRP and adiponectin were unaffected (Table 2),
consistent with other large studies of the relationship
between this adipokine and insulin sensitivity [21].
Iron is linked to the development of diabetes [22] and
ferritin is the major storage form of iron. Chloroquine
treatment was associated with a significant decrease in
ferritin levels in humans (Table 2), confirming an effect
seen in rodents [23].

Table 2 Dose effect of chloroquine on blood pressure and other variables
Variable
SBP (mmHg)
DBP (mmHg)
MAP (mmHg)
Overnight MAP dip
Fasting glucose clamp
Fasting glucose OGTT
OGTT AUC (mmol/L/h)
Weight (kg)
BMI
A1c (%)
Insulin (pmol/L)
C peptide (nmol/L)
Glucagon (pg/mL)
Leptin (μg/L)
NEFA (mmol/L)
TNFα (pg/mL)
Fibrinogen (μmol/L)
IL-6 (pg/mL)
Lp(a) (mg/dL)
CRP (mg/L)
Adiponectin (μg/mL)
Iron (μmol/L)
Iron Bind. Cap. (μmol/L)
Transferrin (mg/dL)
Transferrin Sat. (%)
Ferritin (pmol/L)

Placebo
121 ± 12
70 ± 7

87 ± 8

8.8 ± 4.2

5.77 ± 0.53

5.49 ± 0.57

16.93 ± 3.05
104 ± 18

35.9 ± 4.3
5.8 ± 0.4

153 ± 94

1.16 ± 0.44
110 ± 41

27.5 ± 11.6

0.56 ± 0.15

12.9 ± 1.8

8.44 ± 1.32
1.0 ± 1.6

22.9 ± 17.5
8.3 ± 10.8

21.6 ± 8.1

12.3 ± 4.1

64.9 ± 8.7

300.3 ± 47.5
19.1 ± 6.4

170 ± 191

80 mg/week
121 ± 10

71 ± 7

88 ± 7

9.5 ± 5.3

5.83 ± 0.52

5.77 ± 0.56

17.65 ± 3.00

103 ± 18

35.9 ± 4.2

80 mg/day
123 ± 12

73 ± 8

89 ± 9

9.5 ± 8.8

5.83 ± 0.53

5.72 ± 0.62

17.87 ± 3.22

104 ± 19

250 mg/day
123 ± 12
73 ± 9

90 ± 9

9.6 ± 5.0

5.44 ± 0.65

5.66 ± 0.62

17.26 ± 3.61
103 ± 19

ND

35.9 ± 4.5

ND

35.5 ± 4.6

138 ± 62

166 ± 107

148 ± 80

1.20 ± 0.38

101 ± 26

27.2 ± 11.1

0.55 ± 0.10

13.0 ± 1.7

8.38 ± 1.47

1.4 ± 1.5

20.9 ± 16.0

7.9 ± 10.6

ND

1.26 ± 0.44

111 ± 54

31.0 ± 16.4

0.58 ± 0.19

12.2 ± 1.9

8.14 ± 1.09

1.2 ± 1.6

5.8 ± 0.4

1.25 ± 0.36
102 ± 50

27.2 ± 11.9

0.55 ± 0.16

12.4 ± 2.0

7.94 ± 1.44

0.96 ± 1.3

22.5 ± 17.2

22.8 ± 18.1

ND

20.6 ± 5.6

6.4 ± 7.2

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

7.5 ± 8.0

11.4 ± 5.5

65.8 ± 10.0

303.8 ± 48.5
17.2 ± 6.9
105 ± 88

Data represent mean ± SD

MAP mean arterial pressure, NEFA non-esterified fatty acids, ND not determined
P values determined by repeated measures ANOVA except for A1c, adiponectin, and iron studies, where P value determined by paired t test

P value
0.5607
0.1107
0.1944
0.9878
0.0010*
0.0805
0.3585
0.6041
0.5964
0.9493
0.4260
0.5473
0.3646
0.2134
0.8776
0.0890
0.3563
0.4282
0.1454
0.7455
0.3503
0.5311
0.6385
0.6899
0.3413
0.0155*

McGill et al. Diabetol Metab Syndr

(2019) 11:61

Page 10 of 16

Vascular effects of chloroquine treatment

endpoint of the study (Fig. 4c, P = 0.0697, paired twotailed t test). Representative images of vessels at baseline
and 12 months are shown in Fig. 4d. Carotid dimensions
were also assessed by MRI. Chloroquine was associated
with a decrease in common carotid artery luminal area
(Fig. 4e, P = 0.0033) and diameter (Fig. 4f, P = 0.0019).

Baseline characteristics for the 107 subjects who completed the second trial, a double-blind placebo controlled
study are shown in Table 3. The primary endpoint of
the second trial was CIMT. To validate carotid measurements in this study cohort, baseline CIMT values
for the 116 subjects randomized to chloroquine or placebo were correlated with common variables associated
with atherosclerosis. CIMT was positively correlated
with age (rs = 0.3963, P < 0.0001), systolic blood pressure (rs = 0.3379, P = 0.0002), triglycerides 
(rs = 0.2936,
P = 0.0014), cholesterol 
(rs = 0.3593, P < 0.0001), and
LDL-C (rs = 0.2590, P = 0.0050). There were no correlations with HDL-C, diastolic blood pressure, waist circumference, BMI, glucose, TNFα, IL-6, VEGF, or IL-17A
(not shown).
There was no effect of chloroquine on CIMT after
12 months (Fig. 4b). Because chloroquine has a long
half-life, imaging was repeated at 24 months, following a
12-month washout period. These results also showed no
difference between groups. MRI studies were performed
only at baseline and at 12 months. Chloroquine did not
affect contrast enhancement, a pre-specified secondary

Effects of chloroquine on blood pressure, lipids, and other
variables

Variable

Chloroquine group Placebo group P value

Gender (F/M)

44/12

33/18

0.1108

Age

55 ± 12

55 ± 9

0.9999

6/45/0/0

0.4990

Current

8

10

0.4341

Past

21

23

0.2962

Statin treatment

15

15

0.8310

Hypertension treat‑
ment

20

19

0.9999

Fish oil treatment

5

10

0.1632

Waist circumference

110.4 ± 10.5

108.9 ± 11.8

0.6538

34.2 ± 5.0

0.0433*

Drug treatment over the first year was associated with a
significantly lower diastolic blood pressure (P = 0.0252
at 12 months), results that were driven by a 4.9 mm Hg
decrease at the 6 month time point (Fig. 5a). Ambulatory
monitoring results (performed at baseline, 6 months,
and 12 months but not at 24 months) were consistent
with a beneficial effect of chloroquine on blood pressure. Drug treatment over the first year was associated
with significantly lower daytime mean arterial pressure
(Fig. 5b, P = 0.0484). Daytime (P = 0.0804) and nighttime
(P = 0.0659) systolic pressures by ambulatory monitoring were not different (Fig. 5c, d). By mixed model testing for the interaction between group and time, there
was no effect of chronic chloroquine on lipids. However, at 12 months, a pre-specified secondary endpoint,
total cholesterol was 9% lower (Fig. 5e, P = 0.0089 by
unpaired t test), non-HDL cholesterol was 12% lower
(Fig. 5f, P = 0.0048 by unpaired t test), and LDL-C was
13% lower (Fig. 5g, P = 0.0038 by unpaired t test) in the
chloroquine group. Glucose area under the curve (AUC)
as well as HOMA-IR and the Matsuda index, measures of
insulin sensitivity [24], were not different between groups
(Table 4). There was no effect of chloroquine on insulin
AUC, C peptide AUC, or the insulinogenic index (the
difference between insulin at 30 min and 0 min divided
by the difference between glucose at 30 min and 0 min)
(Table 4), suggesting that chronic chloroquine treatment
at this dose does not impact insulin levels in humans.
Glucagon AUC, creatinine, ALT, and hematologic variables were not different between treatment groups
(Table 4).

137.1 ± 14.3

140.2 ± 13.2

0.2385

134.0 ± 10.1

0.0237*

Potential mechanistic mediators

82.8 ± 9.5

83.0 ± 9.7

0.9483

5.48 ± 0.53

5.52 ± 0.64

0.6960

1.14 ± 0.27

0.9603

3.28 ± 0.82

0.1073

Table 3 Baseline characteristics of subjects in the doubleblind study

Race (AA/NHW/H/NA) 9/45/1/1
Smoking status

BMI
SBP
Screen
Randomization
DBP
Screen
Randomization
Glucose
Triglycerides
HDL-C
Cholesterol
LDL-C
Data represent mean ± SD

36.2 ± 5.0

129.2 ± 11.4

78.3 ± 7.4

1.84 ± 1.04

1.14 ± 0.26

5.00 ± 0.85

3.04 ± 0.68

79.7 ± 7.2

0.3244

1.82 ± 0.93

0.9155

5.18 ± 1.15

0.3834

JNK is a stress kinase implicated in obesity-associated
chronic inflammation [25]. JNK activation in monocytes,
a pre-specified secondary endpoint, was significantly
decreased in chloroquine-treated but not placebo-treated
subjects (Fig. 6a). Reactive oxygen species activate JNK
and have been implicated in the pathophysiology of
obesity-associated conditions [26]. Plasma cholesterol
oxidation products are elevated in diabetes and coronary artery disease [20]. Cholestane-3β, 5α, 6β-triol,
one species that may reflect clinically relevant oxidative

mo P=0.0252
* 12
24 mo P=0.0435
*

a
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Fig. 5 Blood pressure and lipid responses in the yearlong chloroquine trial. a Diastolic blood pressure over 24 months determined by conventional
testing. b–d Blood pressures over 12 months, determined by an ambulatory monitoring device. e–i Lipids and lipoproteins over 24 months. P
values were determined by mixed model treatment of repeated measures

stress [20], was significantly decreased in the chloroquine
group at 12 months (Fig. 6b).
Adverse events

For the dose escalation study, there were no serious
adverse events (Table 5). Not unexpectedly given the rigors of a series of clamps, there were several study-related
events. Of adverse events that were not directly studyrelated, infections were the most common.
For the double blind study, there were 7 serious events.
In the placebo group, one subject presented with a new
diagnosis of prostate cancer. One subject underwent a
right knee replacement. In the chloroquine group, one

patient developed transverse myelitis presenting with
left leg weakness that subsequently improved but did
not completely resolve. One subject underwent carotid
endarterectomy for asymptomatic near-total carotid
occlusion detected at 6 months. One subject was hospitalized for a cutaneous staphylococcus infection that
resolved with appropriate therapy. One subject was
treated for acute appendicitis, stopped the study medication for 1 week then resumed without incident. One subject was found to have a positive PPD without evidence
of pulmonary tuberculosis.
Total adverse events were similar between groups
(Table 6). There were more infectious events in those
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Table 4 Effects of chloroquine vs. placebo over 24 months (off either, i.e. washout, months 12–24)
Variable

Baseline

6 months

12 months

24 months

P value

113.2 ± 16.6

0.5578 (12 m)

Waist (cm)
Chloroquine
Placebo
Weight (kg)
Chloroquine
Placebo
Fasting glucose
Chloroquine
Placebo
Glucose AUC
Chloroquine
Placebo
Insulin AUC
Chloroquine
Placebo
C peptide AUC
Chloroquine
Placebo
HOMA-IR
Chloroquine
Placebo
Matsuda index
Chloroquine
Placebo
Insulinogenic index
Chloroquine
Placebo
Glucagon AUC
Chloroquine
Placebo
Creatinine (μmol/L)
Chloroquine
Placebo
ALT
Chloroquine
Placebo
WBC count
Chloroquine
Placebo
Hemoglobin
Chloroquine
Placebo

110.4 ± 10.5

112.5 ± 12.6

112.6 ± 13.6

108.9 ± 11.8

110.4 ± 13.8

109.8 ± 12.4

102.9 ± 16.7

102.9 ± 16.7

103.1 ± 19.2

99.7 ± 18.5

5.48 ± 0.53

5.52 ± 0.64
16.32 ± 2.46

16.54 ± 3.49
1202 ± 681

1003 ± 524

7.46 ± 2.33

6.49 ± 1.80
3.89 ± 2.23

3.54 ± 2.03
2.89 ± 1.72

3.21 ± 1.89
1.40 ± 1.75

1.05 ± 0.77
174.0 ± 63.5

168.0 ± 60.6
68 ± 14

66 ± 16
26 ± 16

25 ± 12

6.7 ± 1.8

6.5 ± 1.7
13.6 ± 1.1

13.8 ± 0.8

98.7 ± 18.5

5.36 ± 0.55

5.52 ± 0.62
15.94 ± 2.24

99.2 ± 17.8

5.30 ± 0.51

5.51 ± 0.71
16.17 ± 2.58

16.87 ± 3.29

16.43 ± 3.34

1118 ± 542

1143 ± 603

1054 ± 588

7.23 ± 2.10

6.69 ± 2.06
3.85 ± 2.21

3.64 ± 2.08
2.88 ± 1.55

3.07 ± 1.64
1.17 ± 0.87

1.03 ± 0.67
152.3 ± 60.3

138.7 ± 46.7
67 ± 15

65 ± 17
26 ± 19

27 ± 16

6.3 ± 1.6

6.3 ± 1.8
13.3 ± 1.1

13.5 ± 0.9

995 ± 570

7.16 ± 2.20

6.46 ± 2.00
3.57 ± 2.12

3.30 ± 2.23
3.13 ± 2.31

3.50 ± 2.14
1.24 ± 0.87

1.09 ± 0.88
126.8 ± 43.3

108.9 ± 15.9
105.9 ± 20.4

100.5 ± 21.2
5.58 ± 0.73

0.1323
0.1909 (t test 24 m)
0.2741 (12 m)

5.63 ± 0.74

0.0930 (t test 12 m)

16.97 ± 3.20

0.2537

1213 ± 716

0.2479

7.39 ± 2.43

0.2918

3.72 ± 3.53

0.8421

3.43 ± 2.84

0.8997

1.12 ± 0.89

0.4988

ND

0.6126

17.50 ± 3.85

1022 ± 613

6.79 ± 2.06

3.29 ± 2.26

3.56 ± 2.70

1.13 ± 1.62

119.8 ± 36.2

ND

66 ± 15

ND

0.7859

ND

0.2056

65 ± 17
26 ± 15

23 ± 9

6.0 ± 1.5

6.1 ± 1.9
13.2 ± 1.2

13.5 ± 0.9

ND
ND

0.7249

ND
ND

0.8953

ND

Data represent mean ± SD

P values determined by mixed model approach to repeated measures except where indicated

randomized to chloroquine but this was not significant (51 vs. 42, P = 0.0609). No subject in either study
developed retinal pigmentary changes that may occur
with chloroquine. For the double blind study, observers

masked to the treatment assignment examined each subject at 0, 6, 12, and 24 months. Ocular adverse events
were not significantly different between treatment groups
(Table 6).
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Fig. 6 Effects of placebo and chloroquine on potential mechanistic mediators. a Activated JNK in circulating monocytes at baseline and 12 months.
*P = 0.0164; P = 0.3343 for placebo; paired t tests. b Plasma concentrations of the oxysterol cholestane-3β, 5α, 6β-triol at 12 months. *P = 0.0031;
unpaired t test

Table 5 Adverse events in the dose escalation study
Adverse event

Subjects (%)

Total subjects with any event

24 (69)

Subjects with a serious adverse event

0 (0)

Total adverse events

57 (100)

Study related

14 (25)

IV placement difficulties

1 (1.8)

IV infiltration

1 (1.8)

Phlebitis

1 (1.8)

Skin reaction to tape

1 (1.8)

Extremity erythema due to BP cuff

1 (1.8)

Vasovagal episode with IV placement

1 (1.8)

Incorrect stable isotope administered

1 (1.8)

Nausea

3 (5)

Anemia
Not study related
Infectious

4 (7)
43 (75)
15 (26)

Allergy/immunology

3 (5)

Musculoskeletal

8 (14)

CNS

3 (5)

Psychiatric

5 (9)

Cardiovascular

2 (4)

GI

4 (7)

Metabolic

3 (5)

Parentheses denote %

Discussion
We tested the hypothesis that the anti-malarial drug
chloroquine, which activates the kinase ATM, improves
insulin sensitivity and decreases atherosclerosis in
humans with metabolic syndrome. In mice, low dose
chloroquine improves insulin sensitivity, decreases

atherosclerosis, and suppresses activation of JNK in macrophages through pathways that require the presence of
ATM [6]. The absence of ATM in mice affects hepatic
insulin sensitivity and promotes atherosclerosis, suggesting the involvement of processes that link hepatic insulin
resistance and vascular disease. Accordingly, we translated these findings to humans by conducting two trials,
the first to determine if chloroquine improves insulin
sensitivity in the liver, and the second to determine if
chloroquine decreases CIMT.
The overall results were disappointing. Hyperinsulinemic euglycemic clamp studies demonstrated a dose
response relationship between chloroquine administration and hepatic insulin sensitization but the effect was
modest. Treatment with chloroquine for 1 year (using the
lowest dose found to increase hepatic insulin sensitivity)
had no effect on the primary endpoint of CIMT and no
beneficial effects on MRI imaging. One limitation of the
study is that it may have been underpowered to detect a
difference in CIMT. Sample size estimates at the time of
initiation of these studies were based on reports showing that insulin sensitizers had effects on CIMT with
groups of 31–57 subjects [27–30], but subsequent work
indicated the need for larger sample sizes [31]. Taken
together, our findings suggest that chloroquine will
not be clinically useful for the treatment of metabolic
syndrome.
There were positive results from our studies. Chronic
administration of chloroquine lowered blood pressure,
decreased activation of JNK in circulating monocytes,
and decreased concentration of a cholesterol oxidation
product that reflects oxidative stress. These findings
suggest that chloroquine decreases systemic inflammation and improves some components of the metabolic
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Table 6 Adverse events in the double-blind study
Adverse event

Chloroquine subjects (%)

Placebo subjects (%)

P value

Total subjects with any event

44 (76)

39 (67)

0.4107

Subjects with a serious adverse event

5 (9)

2 (3)

0.4385

Total adverse events

109 (100)

105 (100)

–

Infectious

51 (47)

42 (40)

0.0609

Allergy/immunology

5 (5)

10 (10)

0.2681

Musculoskeletal

17 (16)

15 (15)

0.8357

CNS

5 (5)

3 (3)

–

Psychiatric

5 (5)

6 (6)

–

Hematologic/neoplasm

2 (2)

2 (2)

–

Cardiovascular

2 (2)

3 (3)

–

GI

3 (3)

3 (3)

–

GU

2 (2)

2 (2)

–

Metabolic

1 (1)

6 (6)

–

Miscellaneous

0 (0)

3 (3)

–

Ocular

16 (15)

10 (10)

0.2654

Ocular details
Retinal

3

3

–

Lens

4

2

–

Vision

2

0

–

Infectious

2

0

–

Glaucoma

2

2

–

Parentheses denote %
P values determined using contingency tables

syndrome. The inhibition of JNK is known to enhance
insulin sensitivity and decrease atherosclerosis in animals [32, 33]. Oxidative stress activates JNK, and recent
studies implicate ATM, which is activated by chloroquine, in modulation of reactive oxygen species generation [34]. Metformin, the most widely used insulin
sensitizer, appears to work through redox-dependent
mechanisms in liver [35]. Variants in the ATM gene
alter the glycemic response to metformin in humans
[36]. These findings raise the possibility that chloroquine induction of ATM activity modifies redox signaling to decrease insulin resistance, but in humans these
effects are small.
Hydroxychloroquine, closely related to chloroquine,
improves glycemic control in poorly controlled type 2
diabetes in humans [37] and may improve glucose metabolism in human prediabetes [38]. Its use in rheumatoid
arthritis is associated with a reduced risk for developing diabetes in large observational studies [39, 40], and
its administration to healthy obese subjects without the
metabolic syndrome increases the Matsuda index of
insulin sensitivity [41].
Chloroquine was well tolerated. Subjects in the
dose escalation study received 7.2 g and those in the

yearlong study 29.2 g. Retinopathy is a serious but rare
adverse effect of chloroquine; our subjects had regular
eye exams and retinopathy was not detected.

Conclusions
Low dose chloroquine modestly enhanced hepatic insulin sensitivity but did not affect CIMT. Despite some
positive effects on secondary endpoints including the
demonstration of suppression of the stress kinase JNK,
overall results suggest that chloroquine will not be useful for the treatment of metabolic syndrome in humans.
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